- Home
- PSF vs FENC Comparison
PSF vs FENC Comparison
Compare PSF & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PSF | FENC |
|---|---|---|
| Founded | 2010 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.0M | 263.3M |
| IPO Year | N/A | 2001 |
Fundamental Metrics
Financial Performance| Metric | PSF | FENC |
|---|---|---|
| Price | $20.48 | $7.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 25.0K | ★ 118.2K |
| Earning Date | 01-01-0001 | 03-09-2026 |
| Dividend Yield | ★ 7.69% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $38,790,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $70.78 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.00 | $4.68 |
| 52 Week High | $20.19 | $9.92 |
Technical Indicators
Market Signals| Indicator | PSF | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 53.98 | 50.08 |
| Support Level | $20.33 | $7.40 |
| Resistance Level | $20.62 | $8.11 |
| Average True Range (ATR) | 0.15 | 0.28 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 62.79 | 46.03 |
Price Performance
Historical ComparisonAbout PSF Cohen & Steers Select Preferred and Income Fund Inc.
Cohen & Steers Select Preferred and Income Fund Inc is a diversified, closed-end investment company. The Fund's primary investment objective is high current income with capital appreciation as its secondary objective. The Fund invests at least of its Managed Assets in preferred and other income securities issued by U.S. and non-U.S. companies.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.